DPDoctor's PassportEducation
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
RapidMLAMSRAFoundationMRCS

Small intestinal bacterial overgrowth

Essential points for quick revision.

Synopsis

Recognise SIBO as a syndrome arising from impaired clearance or altered anatomy, understand the limitations of breath and aspirate tests, identify nutrient and structural complications, and use short targeted antimicrobial courses with cause correction rather than indefinite empirical cycling.

  • SIBO is an excess or abnormal composition of small-bowel microorganisms causing symptoms or malabsorption; bloating alone is too nonspecific to establish it.
  • Predisposing mechanisms include blind loops, strictures, fistulae, diverticula, scleroderma dysmotility, previous surgery, small-bowel stasis and loss of gastric acid or ileocaecal barrier.
  • Symptoms include bloating, discomfort, diarrhoea, steatorrhoea, weight loss and B12 or fat-soluble vitamin deficiency; methane-associated overgrowth may present with constipation.

Key red flags

Obstruction or ischaemia alarm

Persistent vomiting, colicky focal pain, peritonism, fever or lactate elevation is not uncomplicated SIBO and requires urgent imaging and surgical assessment.

Investigation priorities

01
Anatomy and medicine reviewFirst step

Obtain operation and radiotherapy history, assess strictures, fistulae, diverticula, dysmotility and review opioids, anticholinergics and acid suppression.

Management branches

AssessHigh pre-test probability

Compatible symptoms occur with clear structural, surgical or motility risk.

  1. Exclude acute obstruction, ischaemia and sepsis, then document anatomy, medicine drivers, stool, weight and deficiency phenotype.
  2. Discuss a local validated test or a time-limited empirical antibiotic trial with gastroenterology, defining the expected symptom and nutritional response.

Key medicines

RifaximinSpecialist-selected short oral course using the current local off-label or formulary regimen; dose and duration vary by phenotype and service.
Alternative systemic antibioticA short course of an agent such as co-amoxiclav, metronidazole or another locally approved choice, adjusted for renal function, allergy and previous cultures.
Open full textbook Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom